Jade Biosciences, Inc.
NASDAQ:JBIOBiotechnology
-$0.21 today
- Market cap
- $1.07B
- Beta
- 1.45
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$2.24
Volume 0.79M
Average 0.83M
JBIO Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Jade Biosciences, Inc.NASDAQ: JBIO
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $3.09M rose 255.9% year over year, ahead of the +106.0% change in trailing-twelve-month other income / expenses. Sequentially, it fell 0.4% from the prior quarter.
Context
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +255.9% holds above the trailing-twelve-month pace of +106.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (13.81M) USD
- Year-over-year change
- -374.9%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (13.81M) | -374.9% |
| FY2024 | 2024-12-31 | 5.02M | -15.5% |
| FY2023 | 2023-12-31 | 5.94M | +239.5% |
| FY2022 | 2022-12-31 | 1.75M | +2724.2% |
| FY2021 | 2021-12-31 | 62K | — |
Other Income / Expenses vs competitors
How JBIO compares with its peers on the latest reported figures
- JBIO's LTM Mar 2026 other income / expenses of $4.07M is the 8th highest of the 9 companies compared; the peer median is $8.7M.
- Its year-over-year change of +106.0% is the 2nd highest of 9, against a peer median of -23.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $13.87M | -22.0% | +104.7% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $12.92M | -25.7% | — | — |
| LTM Mar 2026 | $10.82M | -0.5% | +57.2% | 129.3% | |
| LTM Mar 2026 | $8.98M | -61.4% | +194.6% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $8.41M | +109.1% | — | — |
| LTM Mar 2026 | $8.36M | -85.9% | +333.6% | — | |
| LTM Mar 2026 | $7.39M | -51.5% | +158.9% | — | |
| LTM Mar 2026 | $4.07M | +106.0% | — | — | |
| LTM Mar 2026 | $327.6K | +105.1% | — | — | |
| Peer median (excluding JBIO) | $8.7M | -23.9% | +158.9% | 129.3% | |
Competitors are the stored peer set for JBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 15K | 68K | 96K | 282K | 0 |
| Gross Profit | (15K) | (68K) | (96K) | (282K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 14.99M | 38.62M | 64.22M | 53.19M | 93.12M |
| Selling, General & Admin | 8.02M | 14.55M | 17.09M | 21.13M | 20.42M |
| Operating Expenses | 23.01M | 53.17M | 81.31M | 74.31M | 113.54M |
| Depreciation & Amortization | 15K | 68K | 96K | 282K | 26K |
| EBITDA | (22.95M) | (51.42M) | (75.37M) | (69.29M) | (127.33M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (23.02M) | (53.24M) | (81.41M) | (74.6M) | (113.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 65K | 1.83M | 5.95M | 5.04M | 7.78M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 62K | 1.75M | 5.94M | 5.02M | (13.81M) |
| Income Before Tax | (22.96M) | (51.49M) | (75.47M) | (69.57M) | (127.35M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 3K | 25K | 56K | 55K | 58K |
| Net Income | (22.96M) | (51.51M) | (75.52M) | (69.63M) | (127.41M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (32.96) | (73.67) | (100.38) | (85.26) | (4.06) |
| EPS (Diluted) | (32.96) | (73.67) | (100.38) | (85.26) | (4.06) |
| Weighted Avg Shares | 697.44K | 699.2K | 752.33K | 816.63K | 31.36M |
| Weighted Avg Shares (Diluted) | 697.44K | 699.2K | 752.33K | 816.63K | 31.36M |
Jade Biosciences, Inc.
NASDAQ:JBIO
Intrinsic Alpha fair value
Locked
Current Price
$15.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.